Atossa Historical Income Statement

Stocks . USA . 
Stock . Atossa Genetics
ATOS Stock  USD 0.85  0.01  1.19%   
Historical analysis of Atossa Genetics income statement accounts such as Research Development of 14.8 M, Total Operating Expenses of 14.5 M or Depreciation And Amortization of 16.1 K can show how well Atossa Genetics performed in making a profits. Evaluating Atossa Genetics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Atossa Genetics's future profits or losses.
Cash Flow   Balance Sheet     Income Statement
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Atossa Genetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Atossa Genetics is a good buy for the upcoming year.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atossa Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more information on how to buy Atossa Stock please use our How to Invest in Atossa Genetics guide.

About Atossa Income Statement Analysis

Atossa Genetics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Atossa Genetics shareholders. The income statement also shows Atossa investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Balance Sheet
Statement
Details
Cash Flow
Statement
Details

Atossa Genetics Income Statement Chart

At this time, Atossa Genetics' Research Development is comparatively stable compared to the past year. Selling And Marketing Expenses is likely to gain to about 16.9 M in 2025, despite the fact that Operating Income is likely to grow to (26.2 M).
Other Operating Expenses  Research Development  Total Operating Expenses  Selling General Administrative  
Add Fundamental

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Atossa Genetics. It is also known as Atossa Genetics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Most accounts from Atossa Genetics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Atossa Genetics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atossa Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more information on how to buy Atossa Stock please use our How to Invest in Atossa Genetics guide.At this time, Atossa Genetics' Research Development is comparatively stable compared to the past year. Selling And Marketing Expenses is likely to gain to about 16.9 M in 2025, despite the fact that Operating Income is likely to grow to (26.2 M).
 2024 2025 (projected)
Interest Income4.1M4.3M
Non Recurring415.5K394.8K

Atossa Genetics income statement Correlations

Other Operating Expenses
Operating Income
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Net Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Selling And Marketing Expenses
Ebit
Total Other Income Expense Net
Income Tax Expense
Gross Profit
Cost Of Revenue
Net Income From Continuing Ops
Non Operating Income Net Other
Discontinued Operations
Non Recurring
Interest Income
Extraordinary Items
Net Interest Income
Reconciled Depreciation
Other Operating Expenses
-0.950.9-0.961.0-0.95-0.94-0.24-0.010.970.6-0.960.32-0.180.02-0.36-0.950.18-0.46-0.610.570.370.62-0.84
Operating Income
-0.95-0.960.99-0.950.990.980.250.04-0.93-0.660.99-0.410.22-0.010.390.99-0.230.450.64-0.71-0.48-0.760.86
Research Development
0.9-0.96-0.970.9-0.95-0.93-0.470.00.820.7-0.970.48-0.31-0.05-0.55-0.970.22-0.45-0.650.750.50.81-0.91
Ebitda
-0.960.99-0.97-0.960.990.970.350.01-0.92-0.681.0-0.440.240.020.460.98-0.210.510.68-0.68-0.43-0.740.89
Total Operating Expenses
1.0-0.950.9-0.96-0.95-0.94-0.25-0.010.960.6-0.960.32-0.180.01-0.38-0.950.18-0.47-0.610.570.370.62-0.85
Income Before Tax
-0.950.99-0.950.99-0.950.990.26-0.07-0.93-0.660.99-0.310.13-0.020.40.99-0.120.480.65-0.64-0.43-0.70.87
Net Income
-0.940.98-0.930.97-0.940.990.25-0.15-0.93-0.640.97-0.250.030.00.410.98-0.040.510.67-0.61-0.41-0.660.86
Depreciation And Amortization
-0.240.25-0.470.35-0.250.260.25-0.15-0.07-0.470.34-0.370.330.240.910.310.070.340.46-0.28-0.24-0.340.6
Interest Expense
-0.010.040.00.01-0.01-0.07-0.15-0.15-0.060.220.02-0.650.58-0.08-0.15-0.06-0.82-0.26-0.22-0.19-0.12-0.28-0.14
Selling General Administrative
0.97-0.930.82-0.920.96-0.93-0.93-0.07-0.060.57-0.920.3-0.140.05-0.22-0.90.2-0.47-0.60.530.370.57-0.77
Selling And Marketing Expenses
0.6-0.660.7-0.680.6-0.66-0.64-0.470.220.57-0.670.33-0.36-0.41-0.48-0.630.16-0.77-0.910.530.380.48-0.77
Ebit
-0.960.99-0.971.0-0.960.990.970.340.02-0.92-0.67-0.440.240.020.450.98-0.210.50.67-0.68-0.43-0.740.89
Total Other Income Expense Net
0.32-0.410.48-0.440.32-0.31-0.25-0.37-0.650.30.33-0.44-0.79-0.19-0.27-0.330.78-0.1-0.290.710.560.74-0.34
Income Tax Expense
-0.180.22-0.310.24-0.180.130.030.330.58-0.14-0.360.24-0.790.140.120.15-0.770.010.12-0.49-0.28-0.460.28
Gross Profit
0.02-0.01-0.050.020.01-0.020.00.24-0.080.05-0.410.02-0.190.140.10.0-0.210.560.51-0.130.0-0.010.07
Cost Of Revenue
-0.360.39-0.550.46-0.380.40.410.91-0.15-0.22-0.480.45-0.270.120.10.440.110.420.54-0.3-0.27-0.380.66
Net Income From Continuing Ops
-0.950.99-0.970.98-0.950.990.980.31-0.06-0.9-0.630.98-0.330.150.00.44-0.120.440.62-0.66-0.44-0.720.89
Non Operating Income Net Other
0.18-0.230.22-0.210.18-0.12-0.040.07-0.820.20.16-0.210.78-0.77-0.210.11-0.12-0.03-0.090.50.250.46-0.03
Discontinued Operations
-0.460.45-0.450.51-0.470.480.510.34-0.26-0.47-0.770.5-0.10.010.560.420.44-0.030.92-0.150.1-0.090.54
Non Recurring
-0.610.64-0.650.68-0.610.650.670.46-0.22-0.6-0.910.67-0.290.120.510.540.62-0.090.92-0.42-0.28-0.390.71
Interest Income
0.57-0.710.75-0.680.57-0.64-0.61-0.28-0.190.530.53-0.680.71-0.49-0.13-0.3-0.660.5-0.15-0.420.740.96-0.54
Extraordinary Items
0.37-0.480.5-0.430.37-0.43-0.41-0.24-0.120.370.38-0.430.56-0.280.0-0.27-0.440.250.1-0.280.740.76-0.4
Net Interest Income
0.62-0.760.81-0.740.62-0.7-0.66-0.34-0.280.570.48-0.740.74-0.46-0.01-0.38-0.720.46-0.09-0.390.960.76-0.6
Reconciled Depreciation
-0.840.86-0.910.89-0.850.870.860.6-0.14-0.77-0.770.89-0.340.280.070.660.89-0.030.540.71-0.54-0.4-0.6
Click cells to compare fundamentals

Atossa Genetics Account Relationship Matchups

High Positive Relationship

Total Operating Expenses
+ 1.0
Other Operating Expenses
Ebit
+ 1.0
Ebitda
Ebitda
+ 0.99
Operating Income
Income Before Tax
+ 0.99
Operating Income
Ebit
+ 0.99
Operating Income
Net Income From Continuing Ops
+ 0.99
Operating Income

High Negative Relationship

Net Income From Continuing Ops
- 0.97
Research Development
Ebit
- 0.97
Research Development
Ebitda
- 0.97
Research Development
Ebit
- 0.96
Total Operating Expenses
Total Operating Expenses
- 0.96
Ebitda
Research Development
- 0.96
Operating Income

Atossa Genetics income statement Accounts

202020212022202320242025 (projected)
Other Operating Expenses14.6M20.5M27.7M31.4M27.6M14.6M
Operating Income(14.6M)(20.5M)(27.7M)(31.4M)(27.6M)(26.2M)
Research Development6.6M9.2M15.1M17.3M14.1M14.8M
Ebitda(14.6M)(20.5M)(27.7M)(31.4M)(25.5M)(24.2M)
Total Operating Expenses14.6M20.5M27.7M31.4M27.6M14.5M
Income Before Tax(17.8M)(20.6M)(27.0M)(30.1M)(25.5M)(24.2M)
Net Income(21.1M)(20.6M)(26.2M)(30.1M)(25.5M)(24.2M)
Depreciation And Amortization52.8K46.6K23K8K17K16.2K
Selling General Administrative8.0M11.3M12.6M14.0M13.5M9.1M
Ebit(14.6M)(20.5M)(27.7M)(31.4M)(25.5M)(24.2M)
Total Other Income Expense Net(3.2M)(85K)731K1.3M2.1M2.2M
Income Tax Expense(119.1K)3.3M(213.6K)(731K)(840.7K)(798.6K)
Gross Profit(52.8K)(46.6K)(23K)(8K)(17K)(16.2K)
Cost Of Revenue52.8K46.6K23K8K17K16.2K
Net Income From Continuing Ops(17.8M)(20.6M)(27.0M)(29.8M)(25.5M)(24.2M)
Non Operating Income Net Other25.6K(2.3M)(85K)731K657.9K690.8K
Net Income Applicable To Common Shares(17.2M)(22.3M)(20.6M)(27.0M)(24.3M)(25.5M)
Net Interest Income(938.8K)6K877K3.8M4.1M4.3M
Reconciled Depreciation46.5K23K8K11K17K33.2K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Atossa Stock Analysis

When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY